What Cellectar Biosciences, Inc.’s CLOVER WaM data reveals about fixed-duration oncology therapies
Can iopofosine I 131 reshape Waldenström macroglobulinemia treatment? Explore durability data and regulatory outlook driving momentum.
Pharma & Biotech
Pharma & Biotech
How HUTCHMED (China) Limited is positioning HMPL-760 against established BTK therapies in lymphoma care
Can HMPL-760 improve outcomes in relapsed DLBCL? Explore how HUTCHMED is advancing next-gen BTK inhibitors in China.